Lipoprotein-associated Phospholipase A2 and Coronary Heart Disease

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|24|3|291-296

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.24, Iss.3, 2018-04, pp. : 291-296

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lipoprotein-Associated Phospholipase A2: How Effective as a Risk Marker of Cardiovascular Disease and as a Therapeutic Target?

By  

Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy), Vol. 10, Iss. 4, 2011-01 ,pp. : 236-246

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic Modulation of Lipoprotein-associated Phospholipase A2 (Lp-PLA2)

By  

Current Pharmaceutical Design, Vol. 17, Iss. 33, 2011-11 ,pp. : 3656-3661

Bentham Science Publishers

Access to resources Recommend Favorite

Lipoprotein-associated phospholipase A2: a target directed at the atherosclerotic plaque

By Macphee Colin H   Suckling Keith E  

Expert Opinion on Therapeutic Targets, Vol. 6, Iss. 3, 2002-06 ,pp. : 309-314

Informa Healthcare

Access to resources Recommend Favorite

Pathophysiological Role and Clinical Significance of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Bound to LDL and HDL

By  

Current Pharmaceutical Design, Vol. 20, Iss. 40, 2014-12 ,pp. : 6256-6269

Bentham Science Publishers

Access to resources Recommend Favorite

Simvastatin Reduces Expression and Activity of Lipoprotein-associated Phospholipase A2 in the Aorta of Hypercholesterolaemic Atherosclerotic Rabbits

By Qiao Z   Ren J   Chen H  

The Journal of International Medical Research, Vol. 37, Iss. 4, 2009-07 ,pp. : 1029-1037

Field House Publishing

Access to resources Recommend Favorite